FiercePharma  Jun 9  Comment 
These days, companies are increasingly looking to put both branded and generic meds under one roof. And Peter Goldschmidt, the U.S. president of Novartis' Sandoz unit, doesn't know why they didn't do it sooner.
FiercePharma  Jun 8  Comment 
Novartis CEO Joe Jimenez and Chairman Joerg Reinhardt sang the same tune on drug prices in separate interviews over the weekend, backing performance-based drug deals while pointing the finger at other healthcare expenses for driving up overall...
Financial Times  Jun 7  Comment 
New model must be based on patient outcomes if Europe’s health systems are to remain solvent
FiercePharma  Jun 4  Comment 
Now that it's teamed up with Novartis' consumer health unit to form an industry-leading joint venture, GlaxoSmithKline's OTC business is bigger than ever. But its payroll is about to get smaller, with 350 layoffs hitting the operation.
FiercePharma  Jun 4  Comment 
Last month, a U.S. appeals court blocked Novartis' biosimilar version of Amgen's blockbuster Neupogen while the companies worked out a patent dispute. Unsurprisingly, though, Novartis wants that ban lifted, and now it's asking the court to do just...
FierceBiotech  Jun 3  Comment 
Novartis won't be pulling the trigger on a $600 million buyout deal for Israel's Gamida Cell after all. Elbit Imaging, the majority owner of a minority stakeholder in the stem cell player, says that the pharma giant has decided not to pursue its...
FiercePharma  Jun 3  Comment 
Roche has been at the top of the heap in oncology sales for years--and it's no wonder, what with its top-selling triumvirate, Herceptin, Rituxan and Avastin. The Swiss drugmaker racked up more than $25 billion in cancer last year, and its closest...
TheStreet.com  Jun 2  Comment 
NEW YORK (The Deal) -- Ireland's Perrigo said Tuesday it is buying over-the-counter medicines  from a recently formed joint venture between the U.K.'s GlaxoSmithKline  and Novartis AG  of Switzerland. The products have combined...
FiercePharma  Jun 2  Comment 
The U.K.'s cost-effectiveness gatekeeper, the National Institute for Health and Care Excellence (NICE), has bestowed its favor on a crop of new drugs, granting nods to contenders from Roche, Novartis and Bayer.
newratings.com  Jun 2  Comment 
Novartis presents new data at EULAR and WCD further demonstrating its leadership in severe long-term inflammatory and skin conditions Novartis International AG / Novartis presents new data at EULAR and WCD further demonstrating its...


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki